ACRO releases statement on World Heart Day The Association of Clinical Research Companies.

‘Last year, ACRO member companies conducted nearly 600 clinical trials of brand-new treatments and drugs for cardiovascular disease involving 230, 000 patients around the global world,’ stated Doug Peddicord, PhD, Executive Director. ‘Based on the World Heart Association, 17.1 million people die each year from cardiovascular disease, 80 % of whom are in developing countries. These sobering figures highlight the importance of not only conducting further analysis into coronary disease but also ensuring this research is completed globally.’..67 percent). The rates of laboratory abnormalities were identical among the four treatment groupings otherwise. Platelet counts and albumin amounts during treatment are shown in Tables S11 and S12 in the Supplementary Appendix. These rates of response are among the best reported to day for HCV genotype 1 infection. However, this study had not been powered to evaluate responses to regimens with and without ribavirin or even to 12 weeks and 24 weeks of treatment. The analysis population included substantial amounts of patients with characteristics associated with an unhealthy response to treatment historically.15 In particular, 84 to 91 percent of the patients had a non-CC IL28B genotype, 41 to 46 percent experienced a documented prior non-response to interferon-based therapy, and 52 percent got previously been treated with a protease-inhibitor regimen and were therefore with no treatment options.